Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-21-001298
Filing Date
2021-12-17
Accepted
2021-12-17 17:08:53
Documents
2
Group Members
ORBIMED CAPITAL GP VIII LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss688001_sc13da.htm SC 13D/A 131373
2 JOINT FILING AGREEMENT ss688001_ex9901.htm EX-99.1 7644
  Complete submission text file 0000947871-21-001298.txt   140607
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92596 | Film No.: 211502490
SIC: 2834 Pharmaceutical Preparations